Lupin hits new high on USFDA nod for generic hypertension drug
Lupin Pharmaceuticals Inc. received final approval for its Valsartan and Hydrochlorothiazide Tablets, a hypertension drug, from the United States Food and Drugs Administration (USFDA).
Lupin is trading higher by 1.5% at Rs 637 after the company announced that its subsidiary Lupin Pharmaceuticals Inc. received final approval for its Valsartan and Hydrochlorothiazide Tablets, a hypertension drug, from the United States Food and Drugs Administration (USFDA).
“Lupin’s Valsartan and Hydrochlorothiazide Tablets USP is indicated for the treatment of hypertension, to lower blood pressure in patients not adequately controlled with monotherapy or as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals,” Lupin said in a press release.
Valsartan and Hydrochlorothiazide Tablets USP, 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg had annual sales of approximately $1.7 billion in US as per IMS MAT September 2012 sales data, the release said.
The stock opened at Rs 633 and hit a new high of Rs 639 on BSE. A combined 353,757 shares have changed hands on the counter till 1140 hours on BSE and NSE.
“Lupin’s Valsartan and Hydrochlorothiazide Tablets USP is indicated for the treatment of hypertension, to lower blood pressure in patients not adequately controlled with monotherapy or as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals,” Lupin said in a press release.
Valsartan and Hydrochlorothiazide Tablets USP, 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg had annual sales of approximately $1.7 billion in US as per IMS MAT September 2012 sales data, the release said.
The stock opened at Rs 633 and hit a new high of Rs 639 on BSE. A combined 353,757 shares have changed hands on the counter till 1140 hours on BSE and NSE.